• CHMP fandt, at benefit/ risk- forholdet var gunstigt for fluoxetin til behandling af moderate til svære depressive episoder hos børn og voksne i alderen 8 til 18 år.
• the CHMP agreed that the benefits/ risk balance for fluoxetine in the treatment of moderate to severe major depressive episode in children and adolescents aged 8 to 18 is favourable,